The BioHub - by Avetix

Welcome to The BioHub Podcast . I’m joined by Luba Greenwood , CEO of Gallop. Luba’s one of the most respected voices in biotech — a three-time CEO, founder of Binney Street Capital at Dana-Farber, and a driving force behind Biotech Hangout . We talk about Gallop’s mission, what it takes to build strong culture in tough markets, and the personal motivation behind her work after losing her mum to c...

Today we’re joined by a leader at the forefront of next-generation immunotherapy — Dr. Christian Leisner. Christian is the CEO and co-founder of CDR-Life, a biotechnology company pioneering a new class of highly targeted T-cell engaging therapies designed to tackle some of the most difficult-to-treat cancers. With a PhD in Biochemistry from ETH Zurich and a Master’s in Molecular Biology and Chemis...

We were delighted to welcome Dr. Christina Coughlin , CEO of Avacta Therapeutics , onto The BioHub! Avacta are a clinical-stage biotech pioneering next-generation oncology therapies. With a remarkable career spanning top pharmaceutical companies and cutting-edge biotech — from Immunocore and Rubius Therapeutics to Tmunity and CytoImmune — Christina brings a unique blend of medical expertise, scien...

Welcome to another Episode of The Biohub Today, I’m joined by Jill Howe , Chief Financial Officer at Lineage Cell Therapeutics, a company developing groundbreaking allogeneic cell therapies for conditions like dry AMD, spinal cord injury, and hearing loss. Jill’s career spans more than 20 years across some of biotech’s most successful companies, helping take both Receptos and Gossamer Bio public b...

Welcome back to another episode of The BioHub, we were thrilled to introduce a guest whose career lies at the cutting edge of cell therapy, biotech leadership, and real-world impact. Abigail Jenkins is a visionary biotech CEO whose journey has taken her from pioneering the development of cell therapies to leading companies at the forefront of regenerative medicine. Before stepping into her current...

On this episode we welcomed Cameron Turtle, CEO of Spyre Therapeutics during the Jefferies Healthcare conference. Spyre are developing next-generation antibodies, engineered for prolonged activity in the body and formulated for delivery as monotherapies or combination therapies to validated inflammatory targets. Their approach has the potential to deliver uncompromising efficacy and convenience fo...

Today we’re joined by one of Europe’s most respected builders of biotechnology companies — Luc Dochez . Luc is a scientist-turned-entrepreneur whose career has helped shape the next generation of therapies in oncology, rare diseases, and genetic medicine. Over the past two decades, he has co-founded and led multiple biotech companies, including Vico Therapeutics , Montis Biosciences , and Pharvari...

On this episode we're joined by Andrea DiMella - VP & Head of Talent at Atlas Venture - to get her insight into the evolving talent landscape in biotechnology. We talk through Andrea's transition from a laboratory scientist into a transformative TA leader through roles with Genentech, Biogen, Third Rock, and now Atlas Venture. Her learnings throughout this journey are shaping the TA st...

Rita is the CEO of Muna Therapeutics, a biotech company focused on discovering and developing therapies that restore the function of diseased neurons and slow or stop neurodegeneration. In this conversation, we explore Rita’s career journey and what inspired their move into biotech leadership, as well as what first drew them to Muna Therapeutics. We talk about Muna’s scientific focus, how their ap...

Today on The BioHub, I’m joined by Robert Hoffman, Chief Financial Officer of CytoDyn. Robert is a true industry veteran — with decades ofexperience leading finance and strategy across some of biotech’s most recognizable names, from Arena to Heron and Kintara. Over his career he’s guided IPOs, spin-offs, fundraises, and M&A, all while serving on the boards of multiple biotech companies. Now at...

Today, we’re joined by an extraordinary leader who has spent her career at the intersection of science, innovation, and human potential — Dr. Sheila Gujrathi . Sheila is a physician, scientist, engineer, and biotech entrepreneur whose journey embodies both precision and purpose. She earned her Bachelor’s degree in Biomedical Engineering and her M.D. from Northwestern University , before completing...

On this episode we're joined by the Co-Founder & CEO of Tr1X, David de Vries. David and the team are building on the Nobel Prize winning research into T-reg cells of Fred Ramsdell, Shimon Sakaguchi, and Mary Brunkow, pushing that science forward by translating a Type-1 regulatory T cell program into the clinic with one goal - lasting immune balance for patients. Their lead program TRX103 i...

We were honoured to welcome Neha Krishnamohan , onto The BioHub. Neha began her professional journey at Goldman Sachs in theHealthcare Investment Banking Group, focusing on mergers & acquisitions and strategic financings for biotech and med-tech companies. During her time there, she helped execute more than $100 billion in transactions across biopharma, diagnostics and tools. Building on that...

On this episode of the BioHub Podcast we’re joined by the CEO of Alzinova, Tord Labuda. Alzinova are a Gothenburg-based biotech developing an Alzheimer’s vaccine that's just received FDA IND approval and will soon step into ph2 trials.  Alzinova’s products have been developed using their proprietary AβCC peptide™ technology. The technology entails covalent restriction of the amyloid-β (Aβ) pep...

Welcome to The Biohub Joy Clark, Chief People Officer at Worldwide Clinical Trials, joins The BioHub Podcast to talk about building belonging, leading with purpose, and driving health equity in clinical research. Joy shares her journey from high-growth tech to the CRO world, how Worldwide has cultivated a culture that’s 73% women, and why human-centered leadership matters more than ever.

We were thrilled to welcome, Heather Turner, CEO of LB Pharmaceuticals, onto The BioHub. Heather is a seasoned biotechnology executive with over 25 years of experience driving legal, operational, and strategic excellence across the biopharmaceutical industry. She currently serves as CEO of LB Pharmaceuticals, a clinical-stage company focused on innovative treatments for schizophrenia. Under her le...

Today, we’re joined by Clarke Atwell, CEO of Claris Biotherapeutics — a company pioneering regenerative biologic therapies with a focus on transforming the field of ophthalmology. Under Clarke’s leadership, Claris has achieved a major milestone with its Series A financing, fueling the company’s mission to advance novel therapies designed to repair and restore vision at the cellular level, and are...

Today I’m joined by Dr. Maurits Geerlings, President and CEOof NanoCell Therapeutics. Maurits is a true biotech entrepreneur — he’s co-founded and built multiple companies including Actinium Pharmaceuticals, Formula Pharmaceuticals, and Mirata Pharma — and now he’s on a mission to revolutionize in-vivo cell engineering.   In this conversation, we dive into Maurits’ journey, the unique structure of...

Amir Inamdar is the Chief Medical Officer at Cybin Inc., bringing more than 20 years of clinical medicine and drug-development experience. Prior to joining Cybin, Amir held senior roles in industry including Senior Medical Director for R&D Neurosciences at AstraZeneca, Medical Director at Takeda Development Centre Europe Ltd., and Director of Clinical Pharmacology & Discovery Medicine at G...

Today I’m joined by Dena House - Chief People Officer atAdverum Biotechnologies. Dena’s career has spanned some of the world’s leading life sciences companies, from Nikon Precision to Myriad Genetics, but what stands out is her passion for building strong, intentional culture in complex organizations. At Adverum, she was brought in with a clear mission: buildthe kind of people-first culture that c...

We were delighted to welcome Baruch Harris, Chief Operating Officer at Pretzel Therapeutics, a company dedicated to translating mitochondrial biology into transformative therapies. Dr. Harris’s journey spans from rigorous scientific roots to strategic leadership — he holds a Ph. D. in Biochemistry and Molecular Biology from UCSF and a degree in Biophysics from Brown University. Before joining Pret...

Welcome back to another episode of The BioHub, we were delighted to welcome on Abid Ansari, Chief Financial Officer at General Oncology, a clinical-stage biopharma company focused on first-in-class therapies for metastatic cancer. With more than two decades of experience in the biotechnology and life sciences sectors, Abid has built his reputation as a strategic finance executive who bridges capit...

I’m joined by Dr. Paul Song, Chairman & CEO of NKGen Biotech. Paul has led across biotech, from CMO at NKGEN to co-founding Fuse Biotherapeutics and since 2022 he’s been driving NKGen’s mission to harness natural killer cells through their proprietary SNK platform for neurodegenerative diseases and cancer. In this episode, we dive into his decision to return and lead NKGen, the science behind...

On this episode we had the pleasure of featuring Roy Maute of Pheast Therapeutics. Pheast are unleashing the power of macrophages in oncology, starting in advanced solid tumours & Ovarian Cancer. Their pipeline consists of novel innate immune checkpoint inhibitors (incl. Anti-CD24), based on research out of Irv Weissman's lab at Stanford.  In this episode we cover the inspiration behind Ro...